ZEISS O-INSPECT duo: The multifunctional measuring machine

ZEISS O-INSPECT duo combines advanced microscopy and metrology for impressive measurement accuracy.

Svensk obesitaskandidat visade lovande resultat – ”Kan få stor betydelse”

Tabletten ska främja viktminskning utan att påverka aptit eller muskelmassa. Resultaten är lovande, enligt en klinisk fas I-studie från Karolinska institutet oc...

Precision and accuracy in liquid handling

How to evaluate and optimize liquid handling performance

Medivir CEO on upcoming study: ”It's about working together with others”

Medivir is a small company with a big task: to take its drug candidate, via extensive clinical studies, all the way to a patient group that currently lacks appr...

AI automates testing of implant coatings

The medical technology group Smith+Nephew uses an AI-supported light microscope ZEISS Axio Imager to inspect coated implants.

The Swedish innovation model: “There is a paradox”

It is often said that Sweden is strong when it comes to innovation, but how well are we turning that innovation into actual medicines?

Drug development booms in Medicon Valley

When it comes to developing new medicines, the Öresund region is one of the top performers in the EU. Companies working on commission for pharmaceutical compani...

Advancing Drug Discovery by Combining Complex In-Vitro Models with AI-Powered 3D/4D Image Analysis

Free webinar organized by ZEISS.

Wilden för pulveröverföring

Wilden® tryckluftsdrivna membranpump för pulveröverföring. Säker, pålitlig och effektiv

Failed to read the fine print – lost his life’s work

A celebrated CEO and co-founder of a pioneering lab company one moment – the next, fired, kicked out and written out of the company’s history. This is the story...

Unmatched performance and flexibility in its class

The new ZEISS SPECTRUM family is equipped to be the ideal match from measuring small electronics up to larger housings.

JMP Statistical Discovery

Omtalad behandling för urinblåsecancer FDA-godkänd – ”Ett historiskt ögonblick”

En ny typ av behandling för blåscancer har godkänts av amerikanska FDA. Förhoppningen är att Inlexzo ska ge ett nytt alternativ för patienter som annars riskera...

“You discover one thing – and then 10 new questions arise”

COVID-19, diabetes, heart disease, and the impact of dog ownership on humans are just some of multitasker Tove Fall’s areas of research. However, her current fo...

ZEISS presents the "Quality Innovation Summit"

A global event on the future of quality assurance.

Ukraine war fuels rise of totally resistent bacteria

War-torn Ukraine is not just suffering from hostile attacks from a foreign aggressor, but also from the threat of a totally resistant and contagious bacteria.

System Cleaners

Marknadsledare för lågtrycksrengöring inom livsmedels- och dryckesindustrin.

Sobi inleder nytt samarbete inom sepsis

Särläkemedelsbolaget Sobi inleder ett nytt forskningssamarbete och en klinisk studie kring en potentiell behandling vid sepsis.

Obesity-drug pioneers win Lasker Award

This year’s Lasker Prize in Clinical Research has been awarded to three researchers for their discoveries in GLP-1-based drugs that, according to the jury, “hav...

Sahlgrenska Science Park

Cancer researcher: “We can do better and reduce suffering”

Lund University researcher Catharina Hagerling is developing innovative methods to understand metastatic cancer, aiming to create more targeted treatments for p...

Digitala produktpass - från regelverk till konkurrensfördel

Inom EU pågår just nu en omfattande omställning mot mer cirkulära och hållbara affärsmodeller. En viktig pusselbit i detta arbete är införandet av digitala prod...

22 miljarder – så mycket kostar det att utveckla ett nytt läkemedel

Den genomsnittliga kostnaden för Big Pharma att ta ett läkemedel hela vägen från upptäckt till lansering var i fjol 2,23 miljarder dollar, motsvarande en bra bi...

CROs in drug development: "We use our expertise to speed up the process

Consultancy firms have become an increasingly important part of drug development. “It’s a trend and a business model that works, and we see no indication that i...